Literature DB >> 33217150

Uniform 40-µm-pore diameter precision templated scaffolds promote a pro-healing host response by extracellular vesicle immune communication.

Thomas F Hady1, Billanna Hwang2,3, A D Pusic1, Racheal L Waworuntu2, Michael Mulligan2,3, Buddy Ratner1, James D Bryers1,3.   

Abstract

Implanted porous precision templated scaffolds (PTS) with 40-µm spherical pores reduce inflammation and foreign body reaction (FBR) while increasing vascular density upon implantation. Larger or smaller pores, however, promote chronic inflammation and FBR. While macrophage (MØ) recruitment and polarization participates in perpetuating this pore-size-mediated phenomenon, the driving mechanism of this unique pro-healing response is poorly characterized. We hypothesized that the primarily myeloid PTS resident cells release small extracellular vesicles (sEVs) that induce pore-size-dependent pro-healing effects in surrounding T cells. Upon profiling resident immune cells and their sEVs from explanted 40-µm- (pro-healing) and 100-µm-pore diameter (inflammatory) PTS, we found that PTS pore size did not affect PTS resident immune cell population ratios or the proportion of myeloid sEVs generated from explanted PTS. However, quantitative transcriptomic assessment indicated cell and sEV phenotype were pore size dependent. In vitro experiments demonstrated the ability of PTS cell-derived sEVs to stimulate T cells transcriptionally and proliferatively. Specifically, sEVs isolated from cells inhabiting explanted 100 μm PTS significantly upregulated Th1 inflammatory gene expression in immortalized T cells. sEVs isolated from cell inhabiting both 40- and 100-μm PTS upregulated essential Treg transcriptional markers in both primary and immortalized T cells. Finally, we investigated the effects of Treg depletion on explanted PTS resident cells. FoxP3+ cell depletion suggests Tregs play a unique role in balancing T cell subset ratios, thus driving host response in 40-μm PTS. These results indicate that predominantly 40-µm PTS myeloid cell-derived sEVs affect T cells through a distinct, pore-size-mediated modality.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  T cells; biomaterial implant; extracellular vesicles; immune polarization; macrophages; sEV

Mesh:

Year:  2020        PMID: 33217150      PMCID: PMC7954460          DOI: 10.1002/term.3160

Source DB:  PubMed          Journal:  J Tissue Eng Regen Med        ISSN: 1932-6254            Impact factor:   3.963


  38 in total

1.  Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer.

Authors:  Yukiko Tone; Keiji Furuuchi; Yoshitsugu Kojima; Mark L Tykocinski; Mark I Greene; Masahide Tone
Journal:  Nat Immunol       Date:  2007-12-23       Impact factor: 25.606

2.  Porous implants modulate healing and induce shifts in local macrophage polarization in the foreign body reaction.

Authors:  Eric M Sussman; Michelle C Halpin; Jeanot Muster; Randall T Moon; Buddy D Ratner
Journal:  Ann Biomed Eng       Date:  2013-11-19       Impact factor: 3.934

Review 3.  Regulation of immune responses by extracellular vesicles.

Authors:  Paul D Robbins; Adrian E Morelli
Journal:  Nat Rev Immunol       Date:  2014-03       Impact factor: 53.106

Review 4.  Emerging roles for extracellular vesicles in tissue engineering and regenerative medicine.

Authors:  Tek N Lamichhane; Sonja Sokic; John S Schardt; Rahul S Raiker; Jennifer W Lin; Steven M Jay
Journal:  Tissue Eng Part B Rev       Date:  2014-07-24       Impact factor: 6.389

5.  Macrophages play an essential role in antigen-specific immune suppression mediated by T CD8⁺ cell-derived exosomes.

Authors:  Katarzyna Nazimek; Wlodzimierz Ptak; Bernadeta Nowak; Maria Ptak; Philip W Askenase; Krzysztof Bryniarski
Journal:  Immunology       Date:  2015-04-27       Impact factor: 7.397

Review 6.  Cellular and molecular mechanisms of fibrosis.

Authors:  T A Wynn
Journal:  J Pathol       Date:  2008-01       Impact factor: 7.996

7.  Chemokines IL-8, GROalpha, MCP-1, IP-10, and Mig are sequentially and differentially expressed during phase-specific infiltration of leukocyte subsets in human wound healing.

Authors:  E Engelhardt; A Toksoy; M Goebeler; S Debus; E B Bröcker; R Gillitzer
Journal:  Am J Pathol       Date:  1998-12       Impact factor: 4.307

Review 8.  Regulatory role of T cells producing both interferon gamma and interleukin 10 in persistent infection.

Authors:  G Trinchieri
Journal:  J Exp Med       Date:  2001-11-19       Impact factor: 14.307

Review 9.  Regulation of TH17 Cells and Associated Cytokines in Wound Healing, Tissue Regeneration, and Carcinogenesis.

Authors:  Leonie Brockmann; Anastasios D Giannou; Nicola Gagliani; Samuel Huber
Journal:  Int J Mol Sci       Date:  2017-05-11       Impact factor: 5.923

10.  Interleukin 17 and senescent cells regulate the foreign body response to synthetic material implants in mice and humans.

Authors:  Liam Chung; David R Maestas; Andriana Lebid; Ashlie Mageau; Gedge D Rosson; Xinqun Wu; Matthew T Wolf; Ada J Tam; Isabel Vanderzee; Xiaokun Wang; James I Andorko; Hong Zhang; Radhika Narain; Kaitlyn Sadtler; Hongni Fan; Daniela Čiháková; Claude Jourdan Le Saux; Franck Housseau; Drew M Pardoll; Jennifer H Elisseeff
Journal:  Sci Transl Med       Date:  2020-04-15       Impact factor: 19.319

View more
  3 in total

1.  Monocytes contribute to a pro-healing response in 40 μm diameter uniform-pore, precision-templated scaffolds.

Authors:  Nathan R Chan; Billanna Hwang; Buddy D Ratner; James D Bryers
Journal:  J Tissue Eng Regen Med       Date:  2022-01-04       Impact factor: 3.963

Review 2.  Medical Applications of Porous Biomaterials: Features of Porosity and Tissue-Specific Implications for Biocompatibility.

Authors:  Jamie L Hernandez; Kim A Woodrow
Journal:  Adv Healthc Mater       Date:  2022-02-19       Impact factor: 11.092

Review 3.  Biocompatibility Evolves: Phenomenology to Toxicology to Regeneration.

Authors:  Lars Crawford; Meghan Wyatt; James Bryers; Buddy Ratner
Journal:  Adv Healthc Mater       Date:  2021-04-07       Impact factor: 11.092

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.